达沙替尼联合贝林妥欧单抗对比帕纳替尼联合贝林妥欧单抗在新诊断Ph+急性淋巴细胞白血病中的免疫调节作用
本研究分析达沙替尼联合贝林妥欧单抗(dasa+blina)与帕纳替尼联合贝林妥欧单抗(pona+blina)在新诊断Ph+急性淋巴细胞白血病中的免疫调节作用。共153例患者(dasa+blina 43例,pona+blina 110例),dasa+blina在T4和T5时淋巴细胞增加更显著,Treg仅dasa+blina组下降,NK和NK-T细胞在所有时间点显著增加。达沙替尼诱导后完全分子学缓解(CMR)患者淋巴细胞、T细胞和NK细胞显著高于非CMR患者,dasa+blina组NK和NK-T细胞活化标志(CD25、CD69)更高、耗竭标志(PD1、TIM3)更低,提示更强的免疫激活。
要点
- dasa+blina在T4和T5时淋巴细胞增加显著高于pona+blina。
- dasa+blina组Treg下降,NK和NK-T细胞在所有时间点显著增加。
- 达沙替尼诱导后CMR患者淋巴细胞、T细胞和NK细胞显著高于非CMR。
核心结论
- dasa+blina诱导的免疫激活强于pona+blina,支持该药物组合的潜在协同效应。
研究设计与样本
- 研究纳入153例新诊断Ph+急性淋巴细胞白血病患者,其中dasa+blina组43例,pona+blina组110例。
- 在诱导结束时(T0)及第2、4、5个贝林妥欧单抗周期后(T2、T4、T5)分析免疫细胞。
主要发现
- dasa+blina组在T4和T5时淋巴细胞增加显著高于pona+blina组。
- Treg计数仅在dasa+blina组下降。
- NK和NK-T细胞在dasa+blina组所有时间点显著增加。
- 达沙替尼诱导后CMR患者淋巴细胞、T细胞和NK细胞显著高于非CMR患者。
- dasa+blina组NK和NK-T细胞活化标志(CD25、CD69)更高、耗竭标志(PD1、TIM3)更低,NK细胞功能显著增强。
关键数值与推荐
- dasa+blina一线治疗Ph+急性淋巴细胞白血病的长期生存率为75-80%。
临床怎么用
- dasa+blina方案可能通过更强的免疫激活带来协同效应,支持其在新诊断Ph+急性淋巴细胞白血病中的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In Ph+ acute lymphoblastic leukemia, frontline dasatinib plus blinatumomab (dasa+blina) is associated with long-term survival rates of 75-80%. The phase III GIMEMA ALL2820 trial has explored ponatinib with blinatumomab (pona+blina). In the present study, the immune modulation induced by dasa+blina and pona+blina was investigated. Immune cells were analyzed at the end of induction (T0) and after 2, 4 and 5 blinatumomab cycles (T2, T4, T5). Among 153 patients (43 dasa+blina, 110 pona+blina), the dasa+blina combination induced a significantly greater lymphocyte increase at T4 and T5 compared to pona+blina. The Treg counts decreased only in the dasa+blina treated patients. NK and NK-T cells increased significantly in the dasa+blina group, at all timepoints. Complete molecular responders (CMR) after dasatinib induction had significantly higher lymphocytes, T and NK cells compared to non-CMR patients. Bone marrow analyses showed higher activation (CD25, CD69) and lower exhaustion (PD1, TIM3) markers on NK and NK-T cells in dasa+blina treated patients. Dasa+blina patients exhibited a significantly enhanced NK cell capacity compared to ponatinib treated patients. Patients remaining on dasatinib maintained elevated NK cells with a more mature phenotype, suggesting a durable effect. These results highlight the greater dasa+blina immune activation, supporting a potential synergistic effect of the drug combination.
引用
- Ansuinelli M, Peragine N, De Propris MS, et al. Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia. Leukemia. 2026. PMID: 41571767. doi:10.1038/s41375-025-02855-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。